These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 19449006)

  • 1. Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies.
    Lin CC; Beeram M; Rowinsky EK; Takimoto CH; Ng CM; Geyer CE; Denis LJ; De Bono JS; Hao D; Tolcher AW; Rha SY; Jolivet J; Patnaik A
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):167-75. PubMed ID: 19449006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    de Bono JS; Stephenson J; Baker SD; Hidalgo M; Patnaik A; Hammond LA; Weiss G; Goetz A; Siu L; Simmons C; Jolivet J; Rowinsky EK
    J Clin Oncol; 2002 Jan; 20(1):96-109. PubMed ID: 11773159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies.
    Lyass O; Hubert A; Gabizon AA
    Clin Cancer Res; 2001 Oct; 7(10):3040-6. PubMed ID: 11595693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
    Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies.
    Schwartz G; Johnson TR; Goetz A; Burris H; Smetzer L; Lampkin T; Sailstad J; Hohneker JA; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 2001 Jul; 7(7):1901-11. PubMed ID: 11448903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
    Ricart AD; Berlin JD; Papadopoulos KP; Syed S; Drolet DW; Quaratino-Baker C; Horan J; Chick J; Vermeulen W; Tolcher AW; Rowinsky EK; Rothenberg ML
    Clin Cancer Res; 2008 Dec; 14(23):7947-55. PubMed ID: 19047127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
    Lee CK; Rowinsky EK; Li J; Giles F; Moore MJ; Hidalgo M; Capparelli E; Jolivet J; Baker SD
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2158-65. PubMed ID: 16609029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer.
    Flaherty KT; Stevenson JP; Gallagher M; Giantonio B; Algazy KM; Sun W; Haller DG; O'Dwyer PJ
    Cancer; 2003 Apr; 97(8):1985-90. PubMed ID: 12673728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
    Roboz GJ; Giles FJ; Ritchie EK; Allen-Bard S; Curcio TJ; Wilkes MA; Park SL; Kantarjian HM; Faderl S; Ravandi F; Kelner MJ; Feldman EJ
    J Clin Oncol; 2007 Jan; 25(1):10-5. PubMed ID: 17146106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours.
    Kosmas C; Tsavaris NB; Polyzos A; Malamos NA; Katsikas M; Antonopoulos MJ
    Br J Cancer; 2000 Jan; 82(2):300-7. PubMed ID: 10646881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based pharmacokinetic/pharmacodynamic model for troxacitabine-induced neutropenia in cancer patients.
    Ng CM; Patnaik A; Beeram M; Lin CC; Takimoto CH
    Cancer Chemother Pharmacol; 2011 May; 67(5):985-94. PubMed ID: 20614121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
    Tolcher AW; Eckhardt SG; Kuhn J; Hammond L; Weiss G; Rizzo J; Aylesworth C; Hidalgo M; Patnaik A; Schwartz G; Felton S; Campbell E; Rowinsky EK
    J Clin Oncol; 2001 Jun; 19(11):2937-47. PubMed ID: 11387367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and pharmacokinetic study of novel L-nucleoside analog troxacitabine given as a 30-minute infusion every 21 days.
    Bélanger K; Moore M; Baker SD; Dionne J; Maclean M; Jolivet J; Siu L; Soulières D; Wainman N; Seymour L
    J Clin Oncol; 2002 May; 20(10):2567-74. PubMed ID: 12011137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
    Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
    Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
    J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Phase I and pharmocokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies.
    Garrison MA; Hammond LA; Geyer CE; Schwartz G; Tolcher AW; Smetzer L; Figueroa JA; Ducharme M; Coyle J; Takimoto CH; De Jager RL; Rowinsky EK
    Clin Cancer Res; 2003 Jul; 9(7):2527-37. PubMed ID: 12855627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
    Ricart AD; Hammond LA; Kuhn JG; Takimoto CH; Goetz A; Forouzesh B; Forero L; Ochoa-Bayona JL; Berg K; Tolcher AW; Rowinsky EK
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8728-36. PubMed ID: 16361560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.